Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
GLENMARK PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GLENMARK PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
GLENMARK PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 487 | 314 | - | |
Low | Rs | 349 | 226 | - | |
Sales per share (Unadj.) | Rs | 460.4 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 13.4 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 35.0 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 335.1 | 73.3 | - | |
Shares outstanding (eoy) | m | 282.17 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 2.9 | 31.4% | |
Avg P/E ratio | x | 31.3 | -11.5 | -272.2% | |
P/CF ratio (eoy) | x | 11.9 | -13.9 | -86.1% | |
Price / Book Value ratio | x | 1.2 | 3.7 | 33.8% | |
Dividend payout | % | 18.7 | 0 | - | |
Avg Mkt Cap | Rs m | 117,953 | 45,603 | 258.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 27,810 | 2,862 | 971.6% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 129,901 | 15,761 | 824.2% | |
Other income | Rs m | 3,168 | 110 | 2,870.2% | |
Total revenues | Rs m | 133,069 | 15,872 | 838.4% | |
Gross profit | Rs m | 15,125 | -2,731 | -553.8% | |
Depreciation | Rs m | 6,113 | 680 | 898.6% | |
Interest | Rs m | 3,496 | 427 | 818.8% | |
Profit before tax | Rs m | 8,685 | -3,728 | -232.9% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 4,911 | 233 | 2,107.9% | |
Profit after tax | Rs m | 3,774 | -3,971 | -95.0% | |
Gross profit margin | % | 11.6 | -17.3 | -67.2% | |
Effective tax rate | % | 56.5 | -6.2 | -904.9% | |
Net profit margin | % | 2.9 | -25.2 | -11.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 98,737 | 11,544 | 855.3% | |
Current liabilities | Rs m | 50,455 | 6,495 | 776.8% | |
Net working cap to sales | % | 37.2 | 32.0 | 116.0% | |
Current ratio | x | 2.0 | 1.8 | 110.1% | |
Inventory Days | Days | 7 | 111 | 6.0% | |
Debtors Days | Days | 115 | 124 | 92.9% | |
Net fixed assets | Rs m | 76,920 | 6,729 | 1,143.1% | |
Share capital | Rs m | 282 | 73 | 385.6% | |
Net worth | Rs m | 94,563 | 12,371 | 764.4% | |
Long term debt | Rs m | 38,521 | 4,347 | 886.1% | |
Total assets | Rs m | 175,658 | 23,369 | 751.7% | |
Interest coverage | x | 3.5 | -7.7 | -45.1% | |
Debt to equity ratio | x | 0.4 | 0.4 | 115.9% | |
Sales to assets ratio | x | 0.7 | 0.7 | 109.6% | |
Return on assets | % | 4.1 | -15.2 | -27.3% | |
Return on equity | % | 4.0 | -32.1 | -12.4% | |
Return on capital | % | 9.2 | -19.8 | -46.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,254 | 1,345 | 464.9% | |
From Investments | Rs m | -5,285 | -413 | 1,279.4% | |
From Financial Activity | Rs m | -775 | 3,945 | -19.6% | |
Net Cashflow | Rs m | 325 | 4,878 | 6.7% |
Compare GLENMARK PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare GLENMARK PHARMA With: SANOFI INDIA CONCORD BIOTECH AAYUSH FOOD & HERBS EMMESSAR CHM LASA SUPERGENERICS
Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.